Naveed Siddiqi, Novo Holdings 🇬🇧🇩🇰 | Sharp Macro View of EU Biotech | E16 episode artwork

EPISODE · May 27, 2024 · 46 MIN

Naveed Siddiqi, Novo Holdings 🇬🇧🇩🇰 | Sharp Macro View of EU Biotech | E16

from Flot.bio x Philip Hemme · host Flot.bio

We’re in San Sebastián 🇪🇸 with Naveed Siddiqi of one of Europe's largest biotech investors, Novo Holdings. We talked about how things really are in European biotech at the moment. We also talked about his upbringing as a second-generation immigrant in the UK and the importance of diversity. I’ve known him since he was a partner at Andera. He is a sharp investor, but also very friendly and open. 💎 ABOUT THE SPEAKER Naveed has been a part of Novo Holdings since 2019 and splits his time between London and Copenhagen. He has over 25 years of experience in life science venture investment as well as investment banking. Before joining Novo Holdings he was a partner at Andera Partners, a venture capital and growth equity firm with over 2 billion euros to focus on life science investment. 🔗 LINKS MENTIONED -Novo leads Q4 2023 as Top Investor - Oppenheimer: https://drive.google.com/file/d/1b-t2Ba-fnHdyJhIq4j-d7dSCk7Vj65bw/view?usp=sharing - Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group - https://amolytpharma.com/2023/01/06/amolyt-pharma-announces-138-million-series-c-financing-led-by-sofinnova-partners-and-co-led-by-intermediate-capital-group/ - AstraZeneca inks $800M buyout of French biotech to snag phase 3 rare disease drug - https://www.fiercebiotech.com/biotech/astrazeneca-inks-800m-buyout-snag-phase-3-rare-disease-drug - Novo-backed Amolyt Pharma snags $80M series B for endocrine pipeline - https://www.fiercebiotech.com/biotech/novo-backed-amolyt-pharma-snags-80m-series-b-for-endocrine-pipeline 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/naveed-siddiqi-novo-holdings/ 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:02:09] European biotech [00:18:06] Billion dollar exits [00:37:17] Diversity [00:45:04] Thanks for listening

We’re in San Sebastián 🇪🇸 with Naveed Siddiqi of one of Europe's largest biotech investors, Novo Holdings. We talked about how things really are in European biotech at the moment. We also talked about his upbringing as a second-generation immigrant in the UK and the importance of diversity. I’ve known him since he was a partner at Andera. He is a sharp investor, but also very friendly and open. 💎 ABOUT THE SPEAKER Naveed has been a part of Novo Holdings since 2019 and splits his time between London and Copenhagen. He has over 25 years of experience in life science venture investment as well as investment banking. Before joining Novo Holdings he was a partner at Andera Partners, a venture capital and growth equity firm with over 2 billion euros to focus on life science investment. 🔗 LINKS MENTIONED -Novo leads Q4 2023 as Top Investor - Oppenheimer: https://drive.google.com/file/d/1b-t2Ba-fnHdyJhIq4j-d7dSCk7Vj65bw/view?usp=sharing - Amolyt Pharma Announces $138 Million Series C Financing led by Sofinnova Partners and co-led by Intermediate Capital Group - https://amolytpharma.com/2023/01/06/amolyt-pharma-announces-138-million-series-c-financing-led-by-sofinnova-partners-and-co-led-by-intermediate-capital-group/ - AstraZeneca inks $800M buyout of French biotech to snag phase 3 rare disease drug - https://www.fiercebiotech.com/biotech/astrazeneca-inks-800m-buyout-snag-phase-3-rare-disease-drug - Novo-backed Amolyt Pharma snags $80M series B for endocrine pipeline - https://www.fiercebiotech.com/biotech/novo-backed-amolyt-pharma-snags-80m-series-b-for-endocrine-pipeline 📜 TRANSCRIPT Read the full transcript here: https://flot.bio/episode/naveed-siddiqi-novo-holdings/ 🫶 FOLLOW US - Newsletter: http://eepurl.com/h_fnmH - LinkedIn: https://www.linkedin.com/company/flot-bio/ - X (Twitter): https://x.com/FlotBio 🎙️ ABOUT FLOT.BIO Flot.bio is a show to watch the best Europeans in biotech to help you grow. Hosted by Philip Hemme. 15k monthly views. Free. ⭐️ SPONSORSHIP Ready to amplify your brand to influential leaders in biotech and biopharma? Contact [email protected] and unlock sponsorship opportunities in our podcasts! 🙏 LIKE/FOLLOW/REVIEW Did you enjoy the episode? Please hit the like and subscribe button. Also, please let me know your thoughts in the comments below. ⏰ TIMESTAMPS [00:00:00] Intro [00:02:09] European biotech [00:18:06] Billion dollar exits [00:37:17] Diversity [00:45:04] Thanks for listening

NOW PLAYING

Naveed Siddiqi, Novo Holdings 🇬🇧🇩🇰 | Sharp Macro View of EU Biotech | E16

0:00 46:16

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Flot.bio x Philip Hemme?

This episode is 46 minutes long.

When was this Flot.bio x Philip Hemme episode published?

This episode was published on May 27, 2024.

What is this episode about?

We’re in San Sebastián 🇪🇸 with Naveed Siddiqi of one of Europe's largest biotech investors, Novo Holdings. We talked about how things really are in European biotech at the moment. We also talked about his upbringing as a second-generation...

Can I download this Flot.bio x Philip Hemme episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!